A handheld ultrasound device designed to deliver accurate blood pressure monitoring without cuffs, user calibration, or discomfort.
Cardiovascular disease remains the leading cause of death globally, with high blood pressure as its most significant, yet addressable, contributing factor. Despite impacting approximately 1 in 3 adults, nearly 50% of cases remain undiagnosed, reinforcing its status as the "silent killer".
Current monitoring solutions have failed to evolve at the pace required. They remain constrained by legacy cuff-based methods or rely on indirect estimation and user calibration.
SenseBP changes this paradigm. Delivering direct, accurate and reliable measurement, it enables clinicians and users to measure what truly matters.
Global Issue
0.0Billion
People with hypertension
Awareness
0%
Of people unaware they have it
Projected Market
$0.0Billion
Estimated Global Market by 2032
Reliability
±0 mmHg
Clinical Accuracy
SenseBP removes the need for traditional cuffs without compromising accuracy. No compression, no discomfort, and no dependency on correct positioning. A simple interaction at the wrist delivers precise, reliable and repeatable measurements, making blood pressure monitoring effortless and intuitive.
By directly capturing vascular dynamics, SenseBP determines systolic and diastolic blood pressure without the need for user calibration or external reference values. This enables consistent, reliable readings from the very first measurement, with no dependence on repeated measurements or trend analysis.
At the core of SenseBP is Novosound’s thin film ultrasound sensor technology. This enables high-resolution, real-time measurement beneath the skin, capturing arterial motion directly rather than inferring it.
The result is clinical-grade accuracy in a compact form factor, with a technology platform that extends well beyond blood pressure into broader cardiovascular and physiological monitoring.
SenseBP is not just a device. It is the first deployment of a scalable ultrasound sensing platform designed to transform how vital signs are measured across healthcare and consumer markets.
Global demand for continuous, non-invasive monitoring is accelerating rapidly, driven by ageing populations, chronic disease burden, and the shift toward decentralized care. Existing technologies cannot meet this demand at scale with sufficient accuracy.
Novosound is positioned to lead this transition.
Our roadmap enables a clear progression:
